Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

Hans‐Christoph Diener(University of Birmingham), Ḱazunori Toyoda(National Cerebral and Cardiovascular Center), Martina Brueckmann, Jaime Masjuán(Boehringer Ingelheim (Germany)), Robin Lemmens(VIB-KU Leuven Center for Microbiology), Jerzy Krupiński(University Hospital Mútua de Terrassa), Shinichiro Uchiyama(International University of Health and Welfare), Geoffrey A. Donnan(The Royal Melbourne Hospital), J. Donald Easton(University of California, San Francisco), Byung‐Chul Lee(Hallym University), Claudia Grauer(Boehringer Ingelheim (Germany)), José M. Ferro(University of Lisbon), Bernd Kallmünzer(Universitätsklinikum Erlangen), Danilo Toni(Sapienza University of Rome), Jeffrey L. Saver(University of California, Los Angeles), Peter D. Schellinger(University Hospitals of the Ruhr-University of Bochum), Richard A. Bernstein(Northwestern University), Ralph L. Sacco(University of Miami), Martin Grond(Boehringer Ingelheim (Germany)), Jörg Kreuzer(Boehringer Ingelheim (Germany)), M. A. Chernyatina(Boehringer Ingelheim (Germany)), Lisa Cronin(Boehringer Ingelheim (Germany)), Miroslav Odinak(Boehringer Ingelheim (Germany)), Christopher B. Granger(Clinical Research Institute)
New England Journal of Medicine
May 15, 2019
Cited by 809


Related Papers